Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2025

Jun 3, 2025

31565_dirs_2025-06-03_4a734a5e-3709-4977-aa4e-97a1dd049c3e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2025-05-30

Reporting Person: Miller Laurie A. (SVP, Human Resources)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-05-30 Common Stock A 7777 Acquired 28251 Direct
2025-05-30 Common Stock F 2283 $69.38 Disposed 25968 Direct

Footnotes

F1: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025.

F2: This number includes unvested restricted stock units ("RSUs") previously reported.

F3: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.